Evidence mapPaperPMID 41134409Full record

ArticleMetabolic brain disease2025

Polygalasaponin F alleviates cerebral ischemia-reperfusion injury through inhibiting mitophagy.

Siqi Quan, Roujia Guo, Jingjing Bu, Nuo Wang, Yapeng Jia, Jiahui Wang, Ming Bai, Erping Xu, Xiangli Yan, Yucheng Li

Abstract read
PubMed Publisher
In one paragraph

Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Siqi Quan *Collaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao in Henan Province, Henan University of Chinese Medicine, Zhengzhou, 450046, China.
Roujia Guo *Collaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao in Henan Province, Henan University of Chinese Medicine, Zhengzhou, 450046, China.
Jingjing BuCollaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao in Henan Province, Henan University of Chinese Medicine, Zhengzhou, 450046, China.
Nuo WangCollaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao in Henan Province, Henan University of Chinese Medicine, Zhengzhou, 450046, China.
Yapeng JiaCollaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao in Henan Province, Henan University of Chinese Medicine, Zhengzhou, 450046, China.
Jiahui WangCollaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao in Henan Province, Henan University of Chinese Medicine, Zhengzhou, 450046, China.
Ming BaiCollaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao in Henan Province, Henan University of Chinese Medicine, Zhengzhou, 450046, China.
Erping XuCollaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao in Henan Province, Henan University of Chinese Medicine, Zhengzhou, 450046, China.
Xiangli YanCollaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao in Henan Province, Henan University of Chinese Medicine, Zhengzhou, 450046, China. Yanxiangli@hactcm.edu.cn.
Yucheng LiCollaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao in Henan Province, Henan University of Chinese Medicine, Zhengzhou, 450046, China. Liyucheng@hactcm.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurological recovery after ischemic stroke (IS) remains clinically challenging, primarily due to cerebral ischemia-reperfusion injury (CIRI). Oxidative stress contributes to the pathogenesis of CIRI by causing reactive oxygen species excessive accumulation, which disrupts mitochondrial function. Mitophagy maintains mitochondrial function by eliminating damaged or dysfunctional mitochondria. Nevertheless, mitophagy exerts dual effects, either excessive or insufficient activation exacerbates mitochondrial dysfunction. Polygalasaponin F (PGSF), a natural triterpenoid saponin, has been demonstrated to regulate mitochondrial function. Therefore, in this study, we investigated whether PGSF protects against CIRI through inhibiting the mitophagy in vitro and in vivo. Results showed that PGSF attenuated apoptosis both in vivo and in vitro. Moreover, PGSF preserved mitochondrial membrane potential (MMP), reduced mitochondrial reactive oxygen species (mtROS), and ameliorated mitochondrial morphology to improve mitochondrial function in vitro. Furthermore, we revealed that PGSF ameliorates CIRI via modulation of mitophagy, evidenced by a reduced LC3II/LC3I ratio, decreased colocalization of LC3 with mitochondria, while enhancing the levels of TOM20 and p62. In conclusion, our findings imply that PGSF alleviates CIRI through inhibiting mitophagy and reducing apoptosis, demonstrating its therapeutic potential.

Indexed as

Brain IschemiaMitophagyNeuroprotective AgentsReperfusion InjurySaponinsTriterpenesAnimalsApoptosisMaleMembrane Potential, MitochondrialMiceMice, Inbred C57BLMitochondriaOxidative StressReactive Oxygen SpeciesNeuroprotective AgentsReactive Oxygen SpeciesSaponinsTriterpenesCerebral ischemia-reperfusion injuryIschemic strokeMitophagyNeuroprotectionPolygalasaponin F

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.